- Home
- TKC vs RYTM Comparison
TKC vs RYTM Comparison
Compare TKC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKC
- RYTM
- Stock Information
- Founded
- TKC 1993
- RYTM 2008
- Country
- TKC Turkey
- RYTM United States
- Employees
- TKC N/A
- RYTM N/A
- Industry
- TKC Telecommunications Equipment
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- TKC Telecommunications
- RYTM Health Care
- Exchange
- TKC Nasdaq
- RYTM Nasdaq
- Market Cap
- TKC 5.2B
- RYTM 5.9B
- IPO Year
- TKC 2000
- RYTM 2017
- Fundamental
- Price
- TKC $5.82
- RYTM $97.61
- Analyst Decision
- TKC
- RYTM Strong Buy
- Analyst Count
- TKC 0
- RYTM 13
- Target Price
- TKC N/A
- RYTM $101.92
- AVG Volume (30 Days)
- TKC 564.0K
- RYTM 578.8K
- Earning Date
- TKC 08-13-2025
- RYTM 08-05-2025
- Dividend Yield
- TKC 4.05%
- RYTM N/A
- EPS Growth
- TKC N/A
- RYTM N/A
- EPS
- TKC 0.27
- RYTM N/A
- Revenue
- TKC $4,477,787,571.00
- RYTM $156,287,000.00
- Revenue This Year
- TKC $40.02
- RYTM $37.86
- Revenue Next Year
- TKC $28.18
- RYTM $72.72
- P/E Ratio
- TKC $8.69
- RYTM N/A
- Revenue Growth
- TKC 6.41
- RYTM 53.55
- 52 Week Low
- TKC $5.54
- RYTM $43.57
- 52 Week High
- TKC $7.75
- RYTM $99.04
- Technical
- Relative Strength Index (RSI)
- TKC 49.37
- RYTM 73.48
- Support Level
- TKC $5.76
- RYTM $95.30
- Resistance Level
- TKC $6.07
- RYTM $99.04
- Average True Range (ATR)
- TKC 0.08
- RYTM 3.21
- MACD
- TKC 0.03
- RYTM 0.20
- Stochastic Oscillator
- TKC 51.92
- RYTM 90.50
About TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.